Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required |
| |
| Authors: | Tarun Sahu Henu Kumar Verma Lakkakula V K S Bhaskar |
| |
| Institution: | Tarun Sahu, Department of Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, IndiaHenu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 85764, GermanyLakkakula V K S Bhaskar, Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India |
| |
| Abstract: | Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. |
| |
| Keywords: | COVID-19 Co-infection Bacterial co-infection Fungal co-infection |
|
| 点击此处可从《》浏览原始摘要信息 |
|
